Fingolimod Immune Effects Beyond Its Sequestration Ability

Fingolimod Immune Effects Beyond Its Sequestration Ability

Abstract Fingolimod is the first orally administered drug approved for the treatment of relapsing–remitting multiple sclerosis (MS). This drug, modulating sphingosine receptors, regulates the trafficking of lymphocytes between primary and secondary lymphoid organs, trapping naïve T cells and central...

Full description

Bibliographic Details
Main Authors: Francesco Sica, Diego Centonze, Fabio Buttari
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-11-01
Series:Neurology and Therapy
Subjects:
B lymphocytes
Fingolimod
T lymphocytes
Mechanism of action
Online Access:http://link.springer.com/article/10.1007/s40120-019-00162-7

Internet

http://link.springer.com/article/10.1007/s40120-019-00162-7

Similar Items